GPT Healthcare share price today

GPT Healthcare Ltd's share price was ₹141.04 at the close on 4 November 2026. It has been rising for 20 weeks. That is 4.3% below its average price over the last 200 trading days. In the last 52 weeks it traded between ₹116 and ₹170, and at that close it sat 46% of the way up from that low.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today GPT Healthcare Ltd is in stage 2. The phase helps read everything below.

Over the past 13 weeks it has done worse than the NIFTY 500, and it has been behind for 5 weeks running.

Over the last 2.7 years the share price moved −26% while the NIFTY 500 moved +11%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 1 October 2026. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

Three changes stood out: revenue up on a year earlier for 7 quarters in a row, indian funds and insurers (DIIs) raised their stake for 3 quarters in a row and operating margin up 3 points on a year earlier.

1. Revenue up on a year earlier for 7 quarters in a row

   In the June 2026 quarter revenue was ₹126 crore, +17.8% on a year earlier.

2. Indian funds and insurers (DIIs) raised their stake for 3 quarters in a row

   From 6.2% to 7.1% of the company by the September 2026 quarter.

3. Operating margin up 3 points on a year earlier

   19% in the June 2026 quarter, from 16%.

   Why: Operating margin rose because prices rose with inflation and the mix of cases changed.

   Next results: check whether Raipur losses shrink, since new hospital losses pull down company-wide profit.

   From the earnings call on 28 Sep 2026.

For April to June 2026 (the quarter ended 30 June 2026), GPT Healthcare reported revenue of ₹126 crore, up 17.8% from ₹107 crore a year earlier, and a profit of ₹13.0 crore, up 62.5% from ₹8.00 crore.

GPT Healthcare results: April to June 2026 against a year earlier

The next results, for July to September 2026, are due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter).

GPT Healthcare's management discussed these results on a call held on 28 September 2026; what it said is further down this page.

From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.

GPT Healthcare closed at ₹141.04 on 4 November 2026, down 4.6% from ₹147.79 a year earlier (7 November 2025). Its highest weekly close since March 2024 was ₹191.80 on 2 March 2024.

GPT Healthcare share price: then and now

Weekly closing prices. Each change is the move from that price to the 4 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes.

146 weekly closes from 2 March 2024 to 4 November 2026.

4 Nov 2026: GPT Healthcare closed at ₹141.04, up 6.3% on the week and down 6.9% on the month. 28 Sep 2026: GPT Healthcare held its results call for April to June 2026. Management guided: Network to approximately 1,000 beds in the next couple of years, with 10-12% annual bed additions and one new hospital every 18 months.

Earlier

• 30 Jul 2026: ex-date for a dividend of ₹1.50 a share.
• Results for April to June 2026: Revenue up 17.8% and profit up 62.5% on a year earlier.
• 14 Nov 2025: ex-date for an interim dividend of ₹1 a share.

GPT Healthcare paid ₹2.50 a share in regular dividends in the 12 months to 5 November 2026 (2 payments), a yield of 1.77% at the ₹141.04 close on 4 November 2026. The last was a dividend of ₹1.50 a share, ex-date 30 July 2026.

GPT Healthcare dividends since 1 April 2021

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. The record date is the same day as the ex-date for every payment here.

Yes. GPT Healthcare Ltd paid out 49% of its profit as dividends in FY26, and it paid a dividend in 5 of its last 7 reported years.

From the NSE corporate-actions record, read 5 November 2026.

On the call for April to June 2026, held on 28 September 2026, GPT Healthcare's management guided: Network to approximately 1,000 beds in the next couple of years, with 10-12% annual bed additions and one new hospital every 18 months.

“We do not expect to dilute any further from here.”Atul Tantia, on the call for April to June 2026

What management guided

• Revenue yearly growth of approximately 15-17% over the next 4-5 years.
• Consolidated operating margin around 21% after new-hospital losses; mature hospitals around 25%.
• Raipur occupancy around 30% by March and profitability around March.
• Dum Dum and Salt Lake to reach 70% occupancy in the next couple quarters, Agartala near 60% and Howrah 55%; Jamshedpur starts March/April next year, then goals that occupancy level and 22-23% operating margin over five years.

Management’s own plans and goals, from our notes of the call. A plan is not a result.

Source: the call transcript.

From the call for April to June 2026, 28 September 2026.

When GPT Healthcare reports July to September 2026, these are the 3 checks that show whether the story is still on course. First: Raipur ramp: check whether the March profitability milestone is achieved and quarterly losses taper.

GPT Healthcare is on one of our India lists: Dividend stocks.

GPT Healthcare Ltd earned ₹13.0 Cr of net profit in the Jun 2026 quarter, +62.5% on the same quarter a year earlier. That is the 2nd quarter in a row of profit growth. Full-year FY26 profit was ₹42.0 Cr. Over 6 years profit has grown 25.0% a year on average. That is 10.3% of the quarter's revenue.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

The same quarter a year earlier earned ₹8.0 Cr.

For the full year, FY26 profit was ₹42.0 Cr (−16.0% on the year before).

Why profit moved: revenue changed +17.8% on a year earlier and the margin moved +3.0 percentage points. Most of the change came from keeping more of each sale.

On average over the last four quarters, profit changed +6.5% and revenue +18.1%. Profit is growing slower than sales: rising costs are taking part of the growth.

GPT Healthcare Ltd reported ₹126 Cr of revenue in the Jun 2026 quarter, +17.8% on the same quarter a year earlier. That is the 7th quarter in a row with growth on the year before. Over 6 years it has grown 14.3% a year on average. The last full year, FY26, came in at ₹473 Cr.

Revenue is everything the company billed its customers in the period.

The last four reported quarters add to ₹491 Cr.

FY26 revenue was ₹473 Cr, +16.2% on the year before.

Recent pace: the last four quarters grew +18.1% on average, against 14.3% a year over the longer run, so this year is growing faster than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew +18.0%, against +10.5% a year over the last 8 quarters (accelerating); profit over the last 12 months grew +0.0%, against +0.0% a year (stabilising).

GPT Healthcare Ltd's operating margin was 19.0% in the Jun 2026 quarter, 3.0 percentage points higher than the same quarter a year ago. Across 7 years it has been between 17.0% and 22.0%. The latest quarter is within that range.

Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why the margin moved: operating margin changed +2.9 percentage points on the year while gross margin changed +0.2 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales.

Over the last 3 years, 155% of GPT Healthcare Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹81.0 Cr of operating cash against ₹42.0 Cr of profit.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

After ₹96.0 Cr of spending on assets, free cash was −₹15.0 Cr: it spent more than its operations brought in.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why 155% of profit came in as cash: the cash cycle got 14 days shorter between FY21 and FY26, so cash that used to wait in the business now arrives sooner.

What to look at next: the bigger use of cash is spending on new assets, at 2.8× depreciation over three years. The next section checks what that spending is building.

GPT Healthcare Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was −112 days in FY26, down from −98 days in FY21. It spent ₹176 Cr on assets over the last 3 years. Customers take 16 days to pay, and stock sits for 43 days on average.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

At FY26 sales of ₹473 Cr, each day of that cycle ties up about ₹1.3 Cr, so roughly −₹145 Cr is tied up in the business at any time.

FY26: customers took 16 days to pay and stock sat for 43 days, about 1.4 months of sales sitting as stock, for a full cycle of −112 days, shorter than FY21's −98.

The full loop: cash goes out to suppliers and production on day 0. Stock sits for 43 days. Customers pay about 16 days after that. Suppliers are paid at 170 days. Together that makes the −112-day cycle.

Spending on assets: ₹176 Cr over the last 3 years, against ₹64.0 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹1.0 Cr (FY26): assets paid for that are not earning yet.

In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns.

GPT Healthcare Ltd's P/E is 24.4×, near the low end of its own history: it has been lower only 10% of the time. Its usual P/E (the middle reading) is 27.5×, over 2.7 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.

Why the multiple is where it is: over the past year earnings per share moved −15.3% while the price moved −4.6%. The price did better than earnings, which pushed the multiple up within its own range.

In short: the multiple is low against its own past, so the earnings trend underneath matters more than the multiple.

GPT Healthcare Ltd's business is giving mixed signals. There is no clear direction across the growth lines, with ROCE steady at 19.8%; each line tells part of the story. This is based on 12 quarters of 4 measures.

Every business is somewhere on a path of getting better or worse, and this section names where. The last 12 quarters of growth in revenue, profit and earnings per share, plus the return the business earns on its capital, are read as lines. Getting worse: the lines are falling. Turning around: a low point has just formed and the last few quarters are rising from it. Getting better: the rise from the low has lasted. Growing steadily: steady growth with healthy returns. Slowing from a peak: still high, but slowing. When the lines disagree the result is mixed; too little history means no reading. CAGR (compound annual growth rate) is the steady yearly rate that would turn the starting value into the latest one. It is the fairest way to compare growth over different periods. If the 1-year figure is much bigger than the 10-year one, recent growth is running faster than the long-run trend. A dash means there is no figure for that period, or the starting year was a loss, where a growth rate means nothing.

Why it matters: when the lines disagree, each line above matters more than any single label.

Compound annual growth rate (%)

Compound annual growth rate over each period, %. Revenue, profit and EPS come from yearly figures; the share price row is price growth over the same periods. A dash means no figure for that period, or the starting year was a loss.

GPT Healthcare Ltd earned a ROCE of 20% in FY26. That is up from a low of 14% in FY21. Its return on capital used (ROIC) is 4.0 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 8.9% net margin and 1.02× asset turnover (sales divided by assets).

Return on capital employed (ROCE) is the profit the whole business earns on all the money in it, from shareholders and lenders together. It is the best single test of whether growth adds value or just size.

Why the return is what it is (FY26): a 8.9% net margin × 1.02× asset turnover × 1.73× leverage (assets divided by equity) ≈ 15.7% on equity. The margin does its share; borrowing is a big part of it.

The key test, return on capital used minus the cost of capital: 16.0% − 12.0% = +4.0 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. Positive but thin: it creates value with little room for error.

GPT Healthcare Ltd has total debt of ₹91.0 Cr against shareholder equity of ₹269 Cr as of Jun 2026, so its debt is 0.34× its equity. Year by year, that ratio went from 0.50 in FY23 to 0.34 in FY26. Keep that borrowing in mind when reading the returns on this page.

Debt-to-equity shows how much of the business is paid for with borrowed money. Lower is safer, and the direction matters as much as the level.

Domestic institutions cut their stake in GPT Healthcare Ltd by 3.7 percentage points over 8 quarters, the biggest change among its owners. Domestic institutions now own 7.1% of the company. Foreign institutions moved −1.7 points over the same period, to 3.0%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings.

Who owns the company each quarter: promoters (the founders or controlling owners), foreign institutions, domestic institutions such as mutual funds, and the public. When people close to the business steadily raise their stake, that is worth noticing; a quiet list is also an answer.

Over the last two years: Domestic institutions: −3.7 points over 8 quarters, to 7.1%; Foreign institutions: −1.7 points over 8 quarters, to 3.0%; Promoters: +0.0 points over 8 quarters, to 65.6%.

Why the owners changed: domestic institutions drove it (−3.7 points), together with foreign institutions (−1.7 points). They reduced their stake.

For GPT Healthcare Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date.

The Z-score estimates how far a company is from balance-sheet trouble. Above about 3 is safe; below about 1.8 is the danger zone. It was built for manufacturers, so it is not used for banks and lenders.

61.1 out of 100, rank 6 of 20 in Hospitals, with 81% of the evidence available.

GPT Healthcare Ltd scores 61.1 out of 100 against the 20 companies it is compared with in Hospitals, ranking 6. The valuation scores well, but earnings are not improving yet, so the business does not back up the low multiple so far.

The four parts add up to the total exactly: 15.4 + 18.1 + 18.5 + 9.1 = 61.1. This is the same number shown on the industry page; it is worked out once for the whole group and read here.

What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector.

GPT Healthcare ranks 6 of 20 Hospitals companies on the 4-Factor Sector Score, with 61.1 out of 100.

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read.

The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section.

Related companies: Hospitals, all 20 compared on one page.

GPT Healthcare is the 20th largest of 20 Hospitals companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Artemis Medicare Services, Indraprastha Medical Corporation, Dr Agarwals Eye Hospital, KMC Speciality Hospitals (India), Sakar Healthcare and Shalby. It is the smallest.

Hospitals companies close in size

14. Artemis Medicare Services Ltd ₹4,642 crore
15. Indraprastha Medical Corporation Ltd ₹2,802 crore
16. Dr Agarwals Eye Hospital Ltd ₹2,570 crore
17. KMC Speciality Hospitals (India) Ltd ₹2,420 crore
18. Sakar Healthcare Ltd ₹2,102 crore
19. Shalby Ltd ₹1,303 crore
20. GPT Healthcare Ltd ₹1,089 crore

All 20 Hospitals companies, largest first

Companies close in size in other industries

1539. Shriram Properties Ltd ₹1,091 crore · Realty - Construction & Contracting
1540. Viceroy Hotels Ltd ₹1,090 crore · Hotels
1541. GPT Healthcare Ltd ₹1,089 crore
1542. Raj Rayon Industries Ltd ₹1,084 crore · Textiles - Processing/Texturising
1543. SPML Infra Ltd ₹1,084 crore · Infra - Construction & Contracting

Sector Alpha, written by code from the published numbers. Data as of 4 November 2026.

Every chart on this page is drawn by code from the published figures, with no forecasts and no price opinions.

See the plain-text version of this page.